Spring direct naar de hoofdnavigatie of de inhoud
‘An adequate IP strategy protects innovation and creates new chances’
Home / Experts / Marthe Lindenbergh
Marthe Lindenbergh

Marthe Lindenbergh

  • Life Sciences
  • Trainee Patent Attorney
T +31 30 785 63 74

Marthe Lindenbergh obtained a Bachelor’s and Master’s degree in Biomedical Sciences at Utrecht University. During the Master-phase, she did research internships in the UMC Utrecht and at the University of California, San Francisco. Having specialized in Infection and Immunity, she continued her studies with a PhD track at Utrecht University and the Wilhelmina Children’s Hospital, where she studied the immune-modulatory functions of immune-cell-derived extracellular vesicles. In 2019 she started as a trainee patent attorney at V.O. She obtained her PhD in November 2019.

Continue reading

Working experience

  • Trainee Patent Attorney V.O. (2019-present)
  • PhD University of Utrecht (2014-2018)

Education

  • PhD Infection and Immunity, University of Utrecht (2019)
  • MSc Infection and Immunity, University ofUtrecht (2014)
  • BSc Biomedical Sciences , University of Utrecht (2012)

Publications

  • M. Mues, L. Karra, D. Romero-Moya, A. Wandler, M. J. Hangauer, O. Ksionda, Y. Thus, M.F.S. Lindenbergh, K. Shannon, M. T. McManus, J. P. Roose. “High-complexity shRNA libraries and PI3 kinase inhibition in cancer: high-fidelity synthetic lethality predictions”. Cell Reports 2019
  • M.F.S. Lindenbergh, D.G.J. Koerhuis, E.G.F. Borg, E.M. van ’t Veld, T.A.P. Driedonks, R. Wubbolts, W. Stoorvogel, M. Boes. “Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles”. Front. Imm. 2019
  • M.F.S. Lindenbergh, W. Stoorvogel. “Antigen presentation by extracellular vesicles from professional antigen-presenting cells”.  Annu. Rev. Immunol. 2018
  • A.M. Gram, T. Oosenbrug, M.F.S. Lindenbergh, C. Büll, A. Comvalius, K.J.I. Dickson, J. Wiegant, H. Vrolijk, R.J. Lebbink, R. Wolterbeek, G.J. Adema, M. Griffioen, M.H.M. Heemskerk, D.C. Tscharke, L. M. Hutt-Fletcher, E.J.H.J. Wiertz, R.C. Hoeben, M.E. Ressing. “The Epstein-Barr virus glycoprotein gp150 forms an immune-evasive glycan shield at the surface of infected cells”. PLoS Path. 2016
  • M. van Gent, A.M. Gram, I.G.J. Boer, R.J. Geerdink, M.F.S. Lindenbergh, R.J. Lebbink, E.J. Wiertz, M.E. Ressing. “Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion”.  J. Gen. Virol. 2015.

Languages

  • Dutch
  • English

See also

Also see these experts

Sjoerd Postma

Sjoerd Postma

  • Dutch Patent Attorney
  • Associate
+31 26 368 75 28
Annemiek Tepper

Annemiek Tepper

  • European and Dutch Patent Attorney
  • Partner
+31 50 599 52 24
More experts

News

Fast-track Netherlands Patent Office (OCN) search procedure for corona control products

  The Netherlands Patent Office (OCN), that falls under the Netherlands Enterprise Agency, is offering an accelerated search procedure in digital patent databases for inventions that play a role in controlling the coronavirus. Usually this type of search takes about four weeks, but the OCN is now applying a considerably shorter procedure of only two […]Continue reading

New partners and senior associates at V.O.

As of 1 January 2021, V.O. has two new partners: Tamara Elmore and Annemiek Tepper.Continue reading

COVID-19 update 7

The government measures to combat COVID-19 not only affect business operations but they could also impact you as a patent applicant or patent holder.Continue reading

More news